Consumers can tap interactive packages of Betadine® Cold Defence Nasal Spray
for a chance to win Manchester City FC prizes
OSLO, Norway, December 21, 2017 – Thin Film Electronics ASA (“Thinfilm”) (OSE: THIN; OTCQX: TFECY), a global leader in NFC (near field communication) mobile marketing and smart packaging solutions, today announced Mundipharma as a new customer in the OTC (over-the-counter) healthcare market.
Beginning in December, Mundipharma will leverage Thinfilm’s complete NFC solution to deploy and manage a consumer-focused mobile marketing campaign promoting its BETADINE® Cold Defence nasal spray product. Through the contest, consumers will be able to tap interactive packs of the product with a smartphone for a chance to win prizes, including an all-expenses paid trip for two to a Manchester City soccer game in Manchester, England.
The NFC-powered campaign will launch on December 21st in Singapore’s new Changi Airport T4 – known worldwide as a flagship terminal for innovation and new technology – and will run through the close of the contest on February 28th. In a world first, BETADINE® Cold Defence is currently the exclusive advertiser in T4.
The ‘smart’ packaging for BETADINE® Cold Defence will feature Thinfilm’s NFC SpeedTap™ tags. Each tag contains a unique identifier and fully integrates with Thinfilm’s CNECT™ cloud-based software platform. Mundipharma will use a custom dashboard within CNECT to execute the mobile campaign, manage tag IDs, monitor consumer tapping activity, aggregate data, and analyze results.
“We are always looking for new and more interesting ways to interact with consumers. This ground-breaking collaboration with Thinfilm is the latest in a number of innovative projects we’ve deployed that leverage technology to provide enhanced outcomes for patients and consumers,” said Raman Singh, CEO Mundipharma. “NFC’s ability to facilitate direct, one-to-one dialogues with our consumers via a smartphone is compelling, and we’re excited about the role Thinfilm’s solution is playing in driving the success of this competition.”
The campaign also leverages the global partnership between Mundipharma and Manchester City, with BETADINE® serving as the Club’s Official Healthcare Product Partner. This mobile marketing initiative is part of Mundipharma’s broader efforts to transform itself into a global healthcare technology organization. Mundipharma initially launched BETADINE® Cold Defence earlier this year in select markets in Asia.
“Connecting the physical and digital worlds is becoming a more common practice among leading brands looking to fuel consumer engagement,” said Davor Sutija, CEO of Thinfilm. “Mundipharma’s NFC mobile marketing campaign is a perfect example, and we’re pleased to be working alongside them in partnership on this important project and others in the future.”
About Thin Film Electronics ASA
Thinfilm is a global leader in NFC mobile marketing and smart-packaging solutions using printed electronics technology. The Company creates printed tags, labels, and systems that include memory, sensors, displays, and wireless communication — all at a cost-per-function unmatched by conventional electronic technologies.
Thinfilm offers end-to-end mobile marketing solutions that feature hardware, label/packaging integration services, and comprehensive cloud-based management, reporting and analytics. Collectively, these components deliver a powerful 1-to-1 digital marketing platform through which brands of all sizes can connect directly with consumers, all with the simple tap of a smartphone. The resulting disintermediation of search engines, online marketplaces, and social platforms empowers brands to control messaging, enhance consumer dialogue, build loyalty, increase engagement, and drive sales.
Thinfilm’s roadmap integrates technology from a strong and growing ecosystem of partners to bring intelligence to everyday, disposable items. Its mission is to effectively extend the traditional boundaries of the Internet of Things to fuel the Internet of Everything.
Thin Film Electronics ASA is a publicly listed company in Norway with global headquarters in Oslo, Norway; US headquarters in San Jose, California; and offices in Linköping, Sweden; San Francisco; London; and Shanghai. For more information, visit www.thinfilm.no.
Mundipharma’s independent associated companies are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organization that consistently delivers high quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: www.mundipharma.com.sg
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).
For more information on Thinfilm please contact:
SVP Corporate Communications
Thin Film Electronics ASA
For more information on Mundipharma please contact:
Head of Communications & Digital Strategy
Asia Pacific, Middle East, Africa & Latin America